Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL), a leading provider of advanced therapies for sports medicine and severe burn care, has scheduled its second-quarter 2025 financial results announcement for July 31, 2025.

The company will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights. Investors can access the live webcast through Vericel's Investor Relations website, with presentation slides available during the call. A replay will be accessible until July 31, 2026.

News Market Reaction – VCEL

-2.32%

1 alert

-2.32% News Effect

-$43M Valuation Impact

$1.83B Market Cap

1.2x Rel. Volume

On the day this news was published, VCEL declined 2.32%, reflecting a moderate negative market reaction. This price movement removed approximately $43M from the company's valuation, bringing the market cap to $1.83B at that time.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until July 31, 2026.

To participate by telephone, dial 855-303-0072 or +1 773-305-6837 if connecting from outside the U.S. When connected, please use passcode: 276790.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid^® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com. Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.

Investor Contact:

Eric Burns
ir@vcel.com
+1 (734) 418-4411

FAQ

When will Vericel (NASDAQ:VCEL) report Q2 2025 earnings?

Vericel will report its second-quarter 2025 financial results on Thursday, July 31, 2025.

How can investors access Vericel's Q2 2025 earnings call?

Investors can access the live webcast at 8:30 a.m. ET through the Investor Relations section of Vericel's website at investors.vcel.com/events-presentations. For telephone access, dial 855-303-0072 (U.S.) or +1 773-305-6837 (International) using passcode: 276790.

What is Vericel's main business focus?

Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets.

How long will Vericel's Q2 2025 earnings call replay be available?

The webcast replay will be available until July 31, 2026.